feedback

Course Director

Robin L. Jones, MD
Robin L. Jones, MD

Royal Marsden Hospital and Institute of Cancer Research
London, United Kingdom

Faculty

Shreyaskumar Patel
Shreyaskumar Patel, MD

The University of Texas MD Anderson Cancer Center
Houston, Texas

William Tap
William Tap, MD

Memorial Sloan Kettering Cancer Center
New York, New York

Accredited by

Penn State College of Medicine

Activity Details

Credit Types:CME
Credit Amount:1.5 Credits
Release Date:2017-Dec-01
Expiration Date:2018-Nov-30
Estimated Time for Completion:90 minutes
Registration Required:No
Cost:Free of Charge

Activity Description and Educational Objectives

The soft tissue sarcoma (STS) treatment landscape has expanded to include newer cytotoxic agents and targeted therapy options alongside traditional chemotherapy. Histology remains a key component of treatment selection. This activity, based on a recent live symposium, will feature the latest evidence for recently validated therapies, provide a view of emerging treatment regimens, and offer expert guidance for incorporating these agents into clinical practice to improve patient outcomes. Patient cases are woven throughout the activity to offer real-world insight into the management of STS.

Upon completion of this activity, participants should be better able to:
  • Describe the current sarcoma treatment landscape, including the importance of histology in treatment selection
  • Assess the benefits, limitations, and clinical role of current and emerging treatment options for advanced STS including targeted and cytotoxic therapies and immunotherapies
  • Incorporate novel therapies into the management of patients with advanced STS, including patients with newly diagnosed and previously treated advanced disease
  • Integrate emerging therapies into the management of patients with advanced STS in the context of a clinical trial

Target Audience

This activity has been designed to meet the educational needs of oncologists and other clinicians involved in the management of patients with soft tissue sarcoma.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: December 01, 2017 - November 30, 2018
Time to Complete: 90 minutes

Faculty & Disclosure / Conflict of Interest Policy

In accordance with ACCME requirements, Penn State College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.

Course Director and Moderator

Robin L. Jones, MD
Consultant Oncologist and Head of Sarcoma Unit
Royal Marsden Hospital and Institute of Cancer Research
London, United Kingdom

Robin L. Jones, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Adaptimmune Therapeutics; Bayer; Blueprint Medicines; Deciphera Pharmaceuticals, LLC; Eisai, Co.; Immune Design; Karyopharm Therapeutics; Lilly; PharmaMar; and TRACON Pharmaceuticals, Inc.

Faculty

Shreyaskumar Patel, MD
Robert R. Herring Distinguished Professor of Medicine
Center Medical Director, Sarcoma Center
Deputy Chairman, Dept. of Sarcoma Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Shreyaskumar Patel, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Bayer Corporation; CytRx Corporation; Eisai Inc.; EMD Serono, Inc.; Epizyme, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; and Novartis Pharmaceuticals Corporation.
Grant/Research Support from Eisai Inc.; Janssen Pharmaceuticals, Inc.; and Morphotek.

William Tap, MD
Medical Oncologist
Chief, Sarcoma Medical Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

William Tap, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Adaptimmune Therapeutics; Daiichi Sankyo, Inc.; Eisai Inc.; EMD Serono, Inc.; Immune Design; Janssen Pharmaceuticals, Inc.; Lilly; Novartis Pharmaceuticals Corporation; Plexxikon; and TRACON Pharmaceuticals, Inc.

Medical Director

Marie Becker, PhD
PVI, PeerView Institute for Medical Education

Marie Becker, PhD, has no financial interests/relationships or affiliations in relation to this activity.

Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.

Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.

Providership, Credit & Support

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and PVI, PeerView Institute for Medical Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The Penn State College of Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Information about CME credit for this activity is available by contacting Penn State at 717-531-6483 or ContinuingEd@hmc.psu.edu. Reference course # G6225-18-T.

Providership

This CME activity is jointly provided by Penn State College of Medicine and PVI, PeerView Institute for Medical Education.

Support

This activity is supported by educational grants from Janssen Biotech Administered by Janssen Scientific Affairs, Karyopharm Therapeutics, and Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

About This CME Activity

PVI, PeerView Institute for Medical Education, and Penn State College of Medicine are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Penn State College of Medicine.

Copyright © 2000-2017, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.